Actively Recruiting
Study of Upadacitinib After Skin Cell Transplantation to Treat Vitiligo in Adults Aged 18 to 60
Led by Jilin University · Updated on 2024-12-27
60
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well upadacitinib works after autologous non-cultured epidermal cell suspension transplantation NECS in people with vitiligo. The main goal is to see if taking upadacitinib for a short time after NECS improves the treatments effectiveness. This study compares participants receiving upadacitinib after NECS with those receiving NECS alone. Participants are divided into two groups one group receives upadacitinib 15 mg once daily for 8 weeks after NECS, and the other group receives only the NECS transplantation. The study is randomized and observer blinded, meaning participants are randomly assigned to groups, and observers do not know which treatment is given. This setup helps to compare the effects of adding upadacitinib to the standard treatment. During the study, participants will have scheduled visits where their vitiligo areas are assessed using the T-VASI score over 6 months. Researchers will monitor treatment effects and safety throughout this period. Participants must adhere to visits, treatments, lab tests, and other study procedures. The total participation time includes the treatment period and follow-up assessments to evaluate the treatment outcomes.
CONDITIONS
Brief Title
Efficacy of Upadacitinib After NECS in Vitiligo
Research Team
B
Bing Han
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here